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1. INTRODUCTION 
1.1 Charcot-Marie-Tooth disease 
Inherited neuropathies, collectively known as Charcot-Marie-Tooth 
disease (CMT), are a group of genetically and phenotypically heterogeneous 
peripheral neuropathies associated with mutations or copy number variations in 
over 80 distinct genes.1 Named after the three neurologists who first described 
the condition in 1886, CMT is the most common inherited neuromuscular 
disease.2 CMT is a motor and sensory neuropathy (HMSN) that is closely 
related to two other rarer inherited neuropathies: distal hereditary motor 
neuropathy (dHMN), which has predominantly motor involvement, and 
hereditary sensory/autonomic neuropathy (HSN or HSAN), which involves only 
or predominantly sensory and autonomic nerves. These three disorders 
represent a continuum and are often collectively termed CMT and related 
disorders.3  
CMT is divided into different forms based on the pattern of inheritance 
and neurophysiological studies. Autosomal dominant forms are subdivided into 
demyelinating (CMT1) and axonal (CMT2) forms. CMT4 and CMTX designate 
the autosomal recessive and X-linked forms, respectively.4 The term Dejerine-
Sottas neuropathy (DSN) is currently used primarily to denote severe early-
onset clinical phenotypes regardless of the inheritance pattern.5 The 
classification of CMT has been divided further into subtypes, identified by 
letters, as defined by the mutated gene (Table 1).  
 
Epidemiology 
The prevalence of CMT is about 1 in 2500 people, with a global 
distribution and no ethnic predisposition. CMT1A, associated with 17p11.2 
duplication in the region containing the peripheral myelin protein 22 gene 
(PMP22), is the most common form of CMT and accounts for 60 to 70% of 
demyelinating CMT patients (around 50% of all CMT cases). Mutations in the 
gap junction beta 1 gene (GJB1) causing CMTX result in approximately 10 to 
20% of CMT cases and CMT1B associated with mutations in the myelin protein 
zero gene (MPZ) accounts for less than 5%. Patients with CMT2 are about 20% 
of all cases. The prevalence of hereditary neuropathy with liability to pressure 
palsies (HNPP) is not known, but about 85% of patients with clinical evidence of 
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this syndrome have a chromosome 17p11.2 deletion.6 Although there are many 
genes associated with CMT, mutations in only four genes (PMP22 
duplication/deletion, GJB1, MPZ plus MFN2 in Northern Europe and American 
populations or GDAP1 in Mediterranean populations) account for over 90% of 
CMT cases.6-10 Mutations in the  ganglioside-induced differentiation-associated 
protein 1 gene (GDAP1) lead to both recessive (CMT4A/AR-CMT2K) and 
dominant (CMT2K) form of CMT. Rarer forms include CMT2E due to mutations 
in the neurofilament light chain gene (NEFL), CMT2B associated with Ras-
associated protein RAB7 mutations and CMT2C (TRPV4 gene mutations).11  
 
Clinical Manifestations  
Despite phenotypic variability, there are characteristic clinical patterns for 
many types of CMT (Table 2). The “classical” CMT phenotype consists of 
normal early milestones such as beginning to walk by a year of age. This is 
followed by gradually progressing weakness, and sensory loss during the first 2 
decades of life. The classic phenotype typically features a steppage gait, pes 
cavus, sensory loss in a stocking or glove distribution, inverted champagne 
bottle legs, and atrophy in the hands (Figure 1A, 1B and 1C). Though both 
motor and sensory nerves are usually affected, the more prominent phenotypic 
characteristic is related to motor difficulty in most cases. Physical examination 
shows decreased or absent deep tendon reflexes, often diffusely but always 
involving the Achilles tendon. Findings are usually symmetric. Pronounced 
asymmetries in symptoms suggest HNPP if they are episodic. Otherwise they 
are more consistent with acquired disorders. Patients with classical CMT almost 
always have impaired proprioception with balance difficulty. Affected children 
are usually slow runners and have difficulty with activities that require balance 
(e.g., skating, walking along a log across a stream). Ankle-foot orthotics are 
frequently required by the third decade. Fine movements of the hands for 
activities such as turning a key or using buttons and zippers may be impaired, 
but the hands are rarely as affected as the feet. Deep and superficial muscles 
that are innervated by the peroneal nerve, such as the tibialis anterior and 
peroneus brevis and longus muscles often cause more symptoms than do the 
plantar flexion muscles innervated by the tibial nerve, such as the 
gastrocnemius. As a result, tripping and spraining one's ankle are frequent 
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symptoms. Most patients remain ambulatory throughout life and have a normal 
lifespan.  
However, CMT, as well as genetically, may be clinically heterogenous, 
with variability in the age of onset, speed of progression and 
electrophysiological findings. Onset may differ depending on the genetic 
subtype, including early onset, infantile forms with delayed milestones 
(historically designated DSN) and late-onset, adult forms. Symptoms are usually 
slowly progressive, especially for the classic and late-onset phenotype, but can 
be severe, particularly in early-onset forms.12   
 
Electrophysiology 
Electrophysiological studies allow for classification of CMT into 
demyelinating (CMT1) and axonal (CMT2) forms. The standard cut-off for 
demyelinating motor nerve conduction velocity (MNCV) is 38 m/s in the upper 
extremities. Axonal forms (CMT2) exhibit MNCVs greater than 45 m/s but a 
decrease in compound muscle action potential (CMAP) amplitudes. The 
dominant intermediate forms (I-CMT) show MNCVs between 25-45 m/s. 
Conduction velocities are performed in the upper limbs because CMAP 
amplitudes are often unobtainable in the legs, even for demyelinating forms of 
CMT, due to either conduction failure or secondary axonal degeneration. 
The usual electrodiagnostic finding in demyelinated inherited 
neuropathies is widespread uniform slowing of conduction velocities, as 
opposed to the multifocal segmental slowing found in demyelinating acquired 
neuropathies in which temporal dispersion and conduction blocks are frequently 
seen. Exceptions to this rule are women with CMTX, patients with HNPP and 
some CMT1B cases with specific MPZ mutations. In these cases, focal 
demyelination with temporal dispersion or conduction block can be seen. In 
other cases of CMT1 the finding of focal slowing should raise the possibility of a 
superimposed inflammatory neuropathy.13 
 
Pathobiology 
A common feature of most genes mutated in CMT is the role they play in 
maintaining the structure or function of cellular components of the peripheral 
nervous system, myelinating Schwann cells and the axons they ensheath 
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(Figure 2). Impaired interactions between axons and mutant Schwann cells 
seem to be the common process linking all forms of demyelinating CMT. Most 
cases of CMT1 are caused by mutations in myelin specific genes including 
PMP22 (CMT1A), MPZ (CMT1B) and GJB1 (CMT1X), or other genes 
associated with Schwann cell function, including those that exert transcriptional 
control of myelination and intracellular trafficking. At a pathological level 
dysmyelination, demyelination, remyelination, and axonal loss are characteristic 
features of the various demyelinating forms of CMT1. In DSN, myelin may never 
have formed normally which is referred to as dysmyelination. In CMT1, onion 
bulbs of concentric Schwann cell lamellae are usually present on nerve biopsies 
(Figure 3A and 3B), with loss of both small- and large- diameter myelinated 
fibers and a decrease in the number of myelinated axons. Focal, sausage-like 
thickenings of the myelin sheath (tomacula) are characteristic of HNPP but may 
also be found in other forms of CMT1, particularly CMT1B. In CMT1 disability 
typically correlates better with secondary axonal degeneration than with 
demyelination itself, again demonstrating the importance of Schwann cell–
axonal interactions in demyelinating disease.14  
Several recent studies have demonstrated a susceptibility of Schwann 
cells to mutations yielding misfolded proteins, as seen in certain PMP22 and 
MPZ point mutations.15-17 Misfolded proteins may accumulate in the 
endoplasmic reticulum (ER) of Schwann cells inducing a unfolded protein 
response (UPR); a series of cellular events that help the ER to cope with the 
increased metabolic demand caused by retention of the misfolded protein. This, 
in turn, causes down-regulation of the myelination program genes and 
dedifferentiation of Schwann cells, a toxic gain of function that worsens with the 
demyelination and is potentially amenable to therapeutic intervention.18,19 
Spinal motor neurons and dorsal root ganglion sensory neurons that are 
affected in CMT have particular challenges in maintaining homeostasis, as their 
axons extend up to 1 m distal from the cell body. Since the majority of neuronal 
proteins are synthesized in the cell body, intensive transport of proteins must 
occur between the soma and the axonal extremity via anterograde transport. 
Additionally, signals from the periphery containing toxic or pro-survival factors, 
as well as damaged proteins, return to the cell body via retrograde transport.20 
Indeed, axonal trafficking is emerging as a common theme of various seemingly 
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diverse genes that are associated with CMT type 2. Mutations in genes 
associated with axonal structure and function result in CMT2. Some examples 
include mutations in proteins of the neuronal cytoskeleton (NEFL, CMT2E), 
proteins associated with axonal mitochondrial dynamics (mitofusin 2-MFN2, 
CMT2A and GDAP1, CMT2K) and protein associated with regulation of 
membrane and intracellular trafficking (RAB7, CMT2B, for example). The 
pathological hallmark of CMT2 is axonal degeneration with loss of all types of 
nerve fibers in the absence of onion-bulb formation. 
 
2. BACKGROUND 
 
2.1 CMT and skin biopsy 
The advent of genetic testing has made sural nerve biopsy unnecessary 
for diagnosing most cases of CMT, particularly because the technique is 
somewhat invasive. Unfortunately, this has led to an inability to evaluate 
morphological effects by the various mutations on human nerves. Since animal 
models do not always faithfully reproduce human pathology the lack of human 
nerve tissue has limited investigations into pathogenic mechanisms of CMT. 
Skin biopsies increasingly offer a minimally invasive approach to overcome this 
problem.  
Skin biopsy is commonly performed using a disposable 2-3 mm punch 
under sterile technique with topical anesthesia. There is no need for suture, and 
a barely visible scar may remain. It can be performed in any site of the body, on 
both hairy (shoulder/thigh/leg) and glabrous skin (distal/proximal phalanx of the 
fingers/fingertips). It is a valid tool for studying the innervation of unmyelinated 
(C), small myelinated (A) and large myelinated (A) fibers, after 
immunohistochemistry (IHC) with antibodies against different components of 
both the axons and myelin sheath. Specifically, the innervation of autonomic 
structures can be detected using function-related markers to stain adrenergic, 
noradrenergic and cholinergic fibers.21 
Recent studies have shown that the typical morphological changes of 
myelinated fibers in sural nerve biopsy specimens from patients with CMT can 
be detected also in dermal nerves, widening the applications of skin biopsy. 
Beginning with studies of glabrous and hairy skin these biopsies have already 
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provided pathogenic information in sensory nerves from patients with CMT1A 
such as reduced Meissner corpuscles (MC) density, shortened internodal length 
and abnormal paranodal-juxtaparanodal architecture.22,23 Moreover, reliable 
methods for RNA and protein extraction from human skin biopsy specimens 
have widened this field of research in CMT, giving the opportunity to investigate 
markers otherwise hardly detectable with IHC.24,25 Studies on the molecular 
architecture of myelinated fibers and gene expression can be helpful in 
obtaining information on genotype-phenotype correlation and new insight into 
molecular mechanism of pathology. Following these recent findings, skin biopsy 
has been used as an outcome measure to assess if treatment with ascorbic 
acid can modify the expression of PMP22 in patient with CMT1A.25 
Regarding other forms of CMT, limited studies on cutaneous innervation 
are reported and the data are from either single cases or few patients. 
Moreover, unmyelinated and small myelinated fibers have never been 
described so far, even in CMT1A where their involvement is anecdotally 
reported.  
 
2.2 Axonal degeneration in CMT 
In the peripheral nervous system, Schwann cells tightly communicate 
with axons in order to regulate their development, function and maintenance. 
Schwann cells and axons interact at multiple points along the peripheral nerve, 
including the adaxonal (opposing the axon) membrane, paranodal myelin loops, 
microvilli and juxtaparanodal basal lamina. These interactions are mutually 
beneficial, providing trophic support to the axon and myelinating cues to the 
Schwann cell. An example of this important interaction is the occurrence of 
secondary axonal degeneration in all forms of demyelinating CMT. Indeed, 
although the primary metabolic or structural defect often affects either the 
myelin or the axon, axonal degeneration represents the final common pathway 
in both forms of peripheral neuropathies. In demyelinating neuropathies, the 
secondary axonal degeneration presumably occurs because of inadequate 
Schwann cell support of the axon. In these neuropathies secondary axonal 
degeneration may contribute more to clinical impairment than the primary 
demyelination.26 
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3. AIM OF THE STUDY 
The aim of our project was to study the cutaneous innervation of patients 
with different subtypes of CMT and investigate the pathomechanisms 
underlying each form. We have also evaluated the different amount of axonal 
degeneration in demyelinating and axonal form of CMT. In particular, our work 
was structured in three parts:     
 We evaluated small myelinated and unmyelinated fiber degeneration in 
patients with the most common demyelinating form of CMT (CMT1A) by 
quantifying the epidermal nerve fiber (ENF) density and sudomotor, 
pilomotor, and vasomotor nerves. We compared our morphological 
results to those from functional studies.27  
 We investigated large fiber axonal loss by quantifying MC and 
intrapapillary myelinated endings (IME) in different CMT subtypes, both 
demyelinating and axonal. Moreover, we evaluated morphometric 
changes in myelinated dermal nerves by measuring fiber caliber, 
internodal and nodal gap length.28  
 We studied the expression and assembly of axonal transport proteins 
(neurofilament and -tubulin) in a form of axonal CMT (CMT2E), and the 
effects on fiber caliber and nodal/paranodal regions.29 
 
4. MATERIALS AND METHODS 
 
4.1 Patients 
For the study of small fiber involvement 20 unrelated patients (Table 4) 
(male/female 5/15; mean age 42.9 + 8.4 years) from 20 kinships with a clinical 
and genetic diagnosis of CMT1A were included in the study. Patients were also 
screened to identify and exclude participants with possible alternative causes of 
involvement of small fibers, such as abnormalities of glucose metabolism, 
endocrine function, vitamin E, B12 and folic acid deficiency, hepatic or renal 
failure, HIV, or connective tissue disorders.  
For the evaluation of large fiber loss and morphometric analysis in 
dermal nerves 31 CMT patients were included in the study. Based on molecular 
genetic analysis the following CMT genotypes were included: CMT1A (n= 10), 
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CMTX1 (n= 9), late-onset CMT1B (n= 5), CMT2B (n= 3), CMT2C (n=3) and AR-
CMT2K (n=1).  
Lastly, for the study of the axonal transport we evaluated 9 affected 
individuals from two generations of a large family with a clinical and genetic 
diagnosis of CMT2E (Glu396Lys) (Figure 4).  
All patients were older than 18 years at the time of enrollment and 
underwent neurological examination and standard nerve conduction studies. 
Clinical impairment was assessed using the validated CMT Neuropathy Score 
(CMTNS).30,31  The Institutional Ethics Committee approved the study and a 
written informed consent was obtained from all participants in the study. 
A control population of healthy age- and sex-matched controls was 
included in the study.  
 
4.2 Skin biospy 
All patients underwent skin biopsies that were processed by either 
indirect immunofluorescence or electron microscopy (EM) or western blot (WB) 
analysis. 
 
Immunofluorescence 
Skin samples were obtained with 2-mm punch from the fingertip (at the 
vortex of III finger) or the proximal phalanx of the second finger, and by a 3-mm 
punch from the thigh and distal leg (union of middle third with the lower third). 
Specimens were fixed in cold Zamboni solution, cryoprotected in 20% sucrose 
phosphate-buffered saline (PBS), and cut in 50-m-thick sections by means of a 
sliding microtome. Free-floating sections were incubated overnight with a panel 
of primary antibodies to mark both myelinated and unmyelinated somatic and 
autonomic nerve fibers. Secondary antibodies conjugated with cyanine 2 and 3 
were used to visualize the structures of interest. ULEX Europaeus agglutinin 1 
coupled with cyanine 5 was used to visualize blood vessels and epidermis. 
Antibody features, source, and dilution are listed in table 3. 
 
Quantification of cutaneous nerves - Somatic nerves 
ENF density (number per linear mm) was calculated on 4 sections 
double-stained with protein gene product (PGP) 9.5 and collagen IV (Col IV) 
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according to standard criteria.21 A qualitative evaluation of peptidergic nerve 
fiber populations was performed on 2 sections for each biopsy marked with 
substance P (SubP) and calcitonin gene-related peptide (CGRP). 
Quantification of Meissner corpuscles and intrapapillary myelinated 
endings was performed in glabrous skin samples. Density values (numbers of 
structures per square millimeter) were obtained following previously described 
procedures.32 Receptors whose morphology appeared completely disrupted 
with loss of their coiled shape in PGP stained sections were considered atrophic 
and therefore were not included in the count. 
 
Quantification of cutaneous nerves - Autonomic nerves 
A qualitative evaluation of sudomotor, pilomotor, and vasomotor nerves 
was performed in all skin samples using the pan-neuronal marker PGP and 
selective cholinergic and noradrenergic markers vasoactive intestinal peptide 
(VIP) and dopamine b-hydroxylase (DH).33,34 A quantitative assessment of 
sudomotor nerves in skin samples from the leg from 10 subjects (P1 to P10) 
was also performed. For this purpose, using a non-laser confocal microscope 
(AxioImagerM2 with Apotome2, Zeiss, Jena, Germany), 3D digital images of 
sweat glands were acquired using a 203 objective (Zeiss EC Plan NeoFluar 
203/0.5). To avoid non representative sweat gland fragments, only sweat 
glands at least 25 mm thick were included in quantifications. The total length of 
sudomotor nerves immunoreactive for PGP and VIP was calculated using the 
nerve tracing module Autoneuron, a part of Neurolucida software 
(Microbrightfield Bioscience, Williston, VT). This enabled us to trace nerve fibers 
through 2-m optical sections of confocal z-stacks. Sweat gland volumes were 
calculated by manually tracing the outside contour on alternate optical sections 
of composite confocal images showing PGP 9.5 or VIP with Col IV and ULEX. A 
value of nerve density per gland volume (nm/m3) was obtained. This method 
of quantification was previously validated by comparison with an unbiased 
estimation of sudomotor nerve total length by stereologic measures.35 
 
Morphometric analysis of myelinated nerve fibers 
3D digital images of all myelinated fibers present in 3 PGP/myelin basic 
protein (MBP) double stained sections were acquired using confocal 
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microscopy (Zeiss Apotome2) and a 20x objective for the measurements of 
calibre, internode and nodal gap length (Figure 5A). Internodal and nodal gap 
lengths were measured on the stack of z-series images using Neurolucida or 
Image J software (NIH, Bethesda, MD, USA). Nodal gap was measured as the 
length of the fiber not marked by MBP (Figure 5B1 and 5B2) and it included 
nodal and part of paranodal regions. The measurement of internodal length was 
performed only when 2 consecutive nodes were identified by tracing the 
internode on the Z-stack of confocal images (figure 5B3). Four calibre 
measurements for each internode (Figure 5B4) were obtained and a mean value 
was reported. 32,36 The Pan-Neurofascin/MBP double stained sections (1 section 
for each biopsy) (Figure 5C and 5D1) were used to verify that all the myelin 
gaps along the fibre course corresponded to nodes and to qualitatively evaluate 
the nodal/paranodal region. 
 
Fluorescence quantification 
For the fluorescence quantification parameters including pinhole size, 
detector gain, amplifier offset, amplifier gain and laser intensity were first set for 
normal control tissue, and the same setting used for all samples imaged on a 
given day.37 Both control and patient sample images were obtained at the same 
day after the staining. For each sample five non-overlapping sections were 
acquired. Image analysis was performed using Image J software (NIH, 
Bethesda, MD, USA). Fluorescence intensity was measured for both NF-L 
(neurofilament-light) and PGP 9.5 at the same time, choosing an intensity 
threshold in the PGP channel so that only the axons were highlighted, 
corresponding to our regions of interest on both PGP and NF-L channel. Then 
we calculate the NF-L/PGP ratio in order to obtain a relative value of NF-L 
intensity over the PGP-stained axons and rule out a possible role of nerve fiber 
loss in reduced NF-L staining. Alpha-tubulin fluorescence intensity was 
evaluated as well.  
 
Electron microscopy 
Skin samples for EM study were obtained by a 2.5 mm punch from the 
volar aspect of the forearm. Specimens were fixed in 2.5% glutaraldehyde 
solution overnight, then washed in PBS three times for 10 min, osmicated for 
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1.5 hours, dehydrated and embedded in Epon. The semithin sections (1 μm 
thickness) were stained with Toluidine blue and examined under a light 
microscope. The ultrathin sections were contrasted with lead citrate and uranyl 
acetate and examined under EM (Transmission Electron Micrscope, JEOL 
1230).  
 
Western blot analysis 
Skin samples for WB analysis were obtained by a 3.5 mm punch from the 
shoulder and immediately frozen in liquid nitrogen. Snap frozen samples were 
then pulverized, dissolved in lysis buffer (Radioimmunoprecipitation assay 
(RIPA) buffer, Sigma R0278 and proteinase inhibitors), kept on ice for at least 
30 min and centrifuged at 14000 g for 10 min at 4°C. The protein content of the 
supernatant was determined using a bovine serum albumin standard curve. 
Equal amounts of the protein were loaded on 10% sodium dodecyl sulfate 
(SDS)-polyacrylamide gel electrophoresis (PAGE) gels, and electroblotted onto 
polyvinyl difluoride membranes. The primary antibodies used are listed in table 
3. Horseradish peroxidase-conjugated secondary antibodies (1:5,000-1:20,000 
dilution; Sigma) were detected using enhanced chemiluminescence (ECL) 
reagents (Amersham ECL Prime Western Blotting Detection Reagent, RPN 
2232) with autoradiography film (Kodak Scientific Imaging Film, Blue XB). 
Results were normalized for -tubulin and the control sample signal was used 
as the reference. Moreover, the signal density was calculated by Image J 
software (NIH, Bethesda, MD, USA), the ratio NF-L/-tubulin was obtained for 
both patients and control, and any value less than the control value was 
considered abnormal. 
 
4.3 Functional studies 
 
Small Fiber Neuropathy Symptoms Inventory Questionnaire 
For the study of small fiber involvement all CMT1A patients completed 
the Small Fiber Neuropathy Symptoms Inventory Questionnaire (SFN-SIQ).38 A 
subgroup of 10 patients (P1 to P10) underwent an additional extensive protocol 
to assess autonomic and sensory function. To avoid interferences from stress 
or fatigue with the results of psychophysical QST and the cardiovascular 
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autonomic nervous system testing, the evaluations were performed on 3 
separate days according to the following schedule: CVRs on day 1, DST and 
SSR on day 2, and QST (tactile and thermal thresholds, and mechanical pain 
perception) on day 3.  
The 13-item SFN-SIQ questionnaire was used to provide data on clinical 
symptoms of small nerve fiber impairment. Patients were questioned on the 
occurrence of autonomic and sensory symptoms in their daily life. For each 
item, patients were assigned a score based on occurrence of the symptom: 0= 
never; 1= sometimes; 2= often; 3= always. The scoring ranges from 0 (no 
symptoms) to 39 (all symptoms are always present). 
 
Quantitative sensory testing 
Quantitative sensory testing (QST) was performed on the dorsum of right 
hand and foot for 6 sensory modalities (tactile threshold, thresholds to warm 
and cold innocuous and noxious stimuli, mechanical pain perception) as 
previously described.39 
 
Dynamic sweat test 
Postganglionic sudomotor function was evaluated using the dynamic 
sweat test (DST). Briefly, after stimulation with 1% pilocarpine by iontophoresis 
(5 minutes at 2 mA) on the lateral aspect of distal leg (union of middle third with 
the lower third), sweating output, visualized with colorimetric method, was 
recorded using a video camera. Activated sweat gland density per cm2 and 
sweat volume per gland and per cm2 were calculated analyzing sweat drop 
imprints on seriate frames from digital recording.40 
 
Sympathetic skin response 
Sympathetic skin response (SSR) was recorded at hands and feet after 
random single 1-ms stimuli at the wrist, using surface electrodes; a bandpass of 
0.2–100 Hz was used. The skin temperature was maintained between 32 and 
34°C. 
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Cardiovascular reflexes 
To assess cardiovascular reflexes (CVR), the following tests were 
performed: heart rate variability at rest and during deep breathing, Valsalva 
ratio, 30/15 ratio, and blood pressure changes to standing and to handgrip.41 
 
4.4 Statistical analysis 
Statistical analysis was performed using STATA 12.1 for Windows 
(StataCorp LP, USA). The ANOVA test with the Bonferroni post hoc test for 
parametric variables or the Kruskal-Wallis test for non-parametric variables 
were used. For two group comparison, Student t test for unpaired data and 
Mann-Whitney U-test (when analyzing nonparametric data) were used to 
compare skin biopsy findings from patients and controls. The Spearman rank-
order correlation test was used to investigate the correlations between non 
parametric variables. The Robust test of equality of variance was used for 
verifying the homogeneity of data between groups. A p-value of <0.05 was 
considered signiﬁcant. 
 
5. RESULTS 
 
5.1 Patients 
Disease severity, as determined by the CMTNS, ranged from mild to 
severe impairment (scores between 2 and 30). Individual scores along with 
additional clinical information about the patients are provided in table 4, table 7 
and table 8. 
 
5.2 Small fiber involvement in CMT1A 
 
Skin biopsy findings 
Our findings demonstrated a loss of somatic and autonomic nerve fibers 
in the distal leg and fingertip while cutaneous innervation from the thigh was 
relatively spared (Figure 6). Quantitative assessment of ENF, MC, and IME are 
summarized in table 5. ENF density in fingertip (Figure 6A and 6B) and leg 
(Figure 6E and 6F) was lower (p <0.001) in patients compared to controls, 
supporting a length-dependent small fiber neuropathy. A loss of MC and IME 
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(Figure 6A and 6B) was also found (p <0.001). In our patients the loss of ENF at 
distal leg correlated with the increase in heat-pain thresholds (p <0.05) and with 
tactile thresholds (p<0.05). No ENF density differences were found between 
patients with and without burning pain. Peptidergic (SubP and CGRP 
immunoreactive) fibers appeared poorly represented in skin samples of patients 
compared to controls. All dermal adnexa showed aspects of derangement of 
nerve supply with involvement of sudomotor (Figure 7A and 7B), vasomotor 
(Figure 7C and 7D), and pilomotor (Figure 7E and 7F) fibers. The most 
frequently observed morphologic abnormalities were nerve thickening, a chaotic 
distribution of nerve fibers around dermal annexes, and a loss of the regular 
coiling around tubules or vessels. Quantitative evaluation of sudomotor 
innervation was performed on a total of 195 sweat glands (65 from patients and 
130 from controls, 87 with PGP and 108 with VIP). The density of sudomotor 
nerves was lower (p <0.001) compared to normal healthy controls using both 
the pan-neuronal marker PGP and the selective cholinergic marker VIP (Table 
6) and correlated (p <0.001) with the density of activated sweat gland density 
(figure 8A). Eighty percent of patients had a sudomotor innervation below 5% 
cut-off evaluating PGP-immunoreactive fibers and 90% evaluating VIP-
immunoreactive fibers. The loss of MC correlated with the increase in tactile 
thresholds and with the loss of ENF in the same site. The loss of ENF from 
distal leg correlated with the loss of sudomotor nerve fibers from the same site 
(p <0.05), suggesting a parallel involvement of unmyelinated autonomic and 
somatic nerve fiber populations. Activated sweat gland density after pilocarpine 
stimulation correlated with sudomotor innervation as well as with ENF (p <0.01) 
and MC loss (p <0.05).  
 
Functional studies 
At the SFN-SIQ all patients reported at least 2 symptoms related to 
dysfunction of small nerve fibers (Table 6). Sweating disorders 
(hypohidrosis/hyperhidrosis) (60%), palpitations (50%), and gastrointestinal 
complaints (50%) were most frequently reported. Burning feet occurred in 6 out 
of 20 patients. 
For the QST, the mean values of sensory thresholds for all modalities 
were higher (p <0.01) than those in controls (Table 6). All patients but one had 
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increased thresholds in sensory modalities involving both C and A- fibers, as 
well as an increase in A--fiber–related tactile thresholds. Abnormalities in the 
feet were greater than those in the hands. None of the patients showed thermal 
hyperalgesia. 
At the DST, patients had a marked reduction of both density of activated 
sweat glands and mean sweat output for each gland (p <0.001) (Table 6). 
Hypohidrosis (sweat output/cm2 less than 5° percentile cut-off) was present in 7 
of the 10 patients analyzed. 
The SSR was obtained in all patients in both hands and feet. The 
amplitude of SSR recorded at feet was lower in patients than in age- and sex-
matched controls (p <0.05) (Table 6). 
At the CVR study, only 1 patient showed a cardiac dysautonomia, with 
abnormalities in 2 tests (30/15 ratio and blood pressure changes to standing), 
while 2 patients showed borderline results with abnormalities in only 1 test 
(30/15 ratio) (Table 6).  
The loss of ENF in all the 3 sites, as well as the sensory thresholds, the 
loss of sudomotor nerves, and the deficit in sweating output increased with age. 
The age effect appeared particularly evident on the loss of leg ENF; the age-
disease interaction was significant (p= 0.04) for this parameter in a model of 
multiple linear regression (Figure 8B). 
 
5.3 Large fiber investestigation in different CMT subtypes 
 
Morphological analysis 
All patients from each CMT genotype had a significant loss (p<0.005) of 
MC and IME compared to healthy controls (Table 7). The axonal group as 
whole tended to have a greater loss of MC and IME than CMT1A and this was 
especially evident in CMT2C group and in AR-CMT2K patient who presented a 
complete loss of MC and IME (Table 7). No correlations with disease severity 
was found in any CMT subtypes. In addition to the nerve fibre loss, several 
aspects of nerve degeneration were present. MC showed abnormalities in their 
shape (Figure 9B and 9C compared to 9A) and in their position (located at the 
base instead of the apex of the dermal papillae). 
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Morphometric analysis  
Our findings showed a significant difference in both internodal and nodal 
gap length among the seven groups (p= 0.0001). The two group comparison 
showed that each CMT genotype had shorter internode (p<0.009) and longer 
nodal gap (p<0.0001) compared to healthy controls (table 7). CMT1A had 
significantly shorter internodes (p<0.001) and longer nodal gaps (p<0.001) than 
the axonal CMT group. Moreover, CMT1A patients had significantly (p<0.05) 
longer nodal gaps than any other CMT genotype. No difference was evident 
within the axonal group between patients harbouring mutations in myelin genes 
(i.e. MPZ, GJB1) and those with mutations in axonal genes (i.e. RAB7, TRPV4 
and GDAP1). The variability around the mean internodal length was 
comparable between each CMT genotype and controls suggesting that the 
reduction in internodal length observed in each CMT genotype affected nerve 
fibres uniformly (Figure 10). Fiber calibre was not different among CMT 
genotypes and between each CMT genotype and controls. Myelinated fibres 
showed large variability in the calibre, fragmentation (Figure 9D) and swellings 
(Figure 9E and 9F). Neurofascin/MBP double staining showed asymmetrical 
distribution (Figure 9H and 9I) of paranodes compared to control (Figure 9G).  
Finally, although segmental demyelination and subsequent remyelination 
may be a pathological feature in sural nerve biopsies from CMT1A we identified 
no segmental demyelination in any of internodes from CMT1A patients. These 
data are in keeping with those previously reported in CMT1A patients by 
Saporta et al.23 
 
5.4 Study of the axonal transport proteins in CMT2E 
 
Immunofluorescence and Western blot analysis 
We performed immunohistochemistry on myelinated dermal nerves from 
patients and controls. Results from controls demonstrated many axons labeled 
by the axonal marker PGP 9.5 and with antibodies to NF-L (Figure 11A I, II). 
Alternatively, axons from patients were not labeled with antibodies to NF-L but 
were labeled by PGP (Figure 11A IV, V). In order to measure the difference 
between controls and patients we quantified the fluorescence intensity in the 
two groups. The analysis demonstrated a lower NF/PGP ratio in patients than 
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controls (p< 0.01) (Figure 11B). There was no correlation between NF-L levels 
and clinical severity as measured by the CMTNSv2 (p= NS). We then labeled 
axons with antibodies to -tubulin to determine whether the transport of other 
molecules such as -tubulin was affected by the mutation. Many axons in both 
patients and controls were labeled with -tubulin and no difference in staining 
intensity was detectable between the two groups. In addition, many axons from 
patients but not controls were labeled with -tubulin but not with NF-L (Figure 
11A III, VI). We concluded that the decreased NF-L immuno labeling was not a 
consequence of axonal degeneration but rather was a specific consequence of 
the NF-L mutation. Results from WB analysis confirmed these data as NF-L 
expression was decreased in patients with a complete absence of NF-L band in 
two of them, while -tubulin expression was normal (Figure 11C). The ratio NF-
L/-tubulin was markedly reduced in patients (Figure 11D).  
 
Electron microscopy 
In order to investigate NF accumulation, we also evaluated dermal 
nerves from our patients by electron microscopy (Figure 12A). No abnormalities 
of myelin sheathes were observed on either semi-thin or EM sections. Many 
Schwann cells without axons (bands of Bungner) were present, suggesting prior 
axonal degeneration. No aggregates were observed. Our results were similar to 
what was previously reported in sural nerve biopsies from CMT2E patients with 
Glu396Lys.42,43 
As the aggregates were made up of phosphorylated NF in the mutant 
mouse,44 we performed additional staining with antibodies to phosphorylated NF 
at HIC but again we did not detect any aggregate formation (data not shown). 
Furthermore, previous studies showed that the distribution of 
mitochondria was altered in cultured cells with aggregated NF due to 
expression of CMT-causing NEFL mutants.45 In our patients mitochondria were 
distributed normally into the axons and neither their shape nor their number was 
affected by NF disruption. 
 
Morphometric analysis  
Prior studies have demonstrated a close correlation between the number 
of NF and the diameter of myelinated axons in the peripheral nervous 
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system.46,47 To determine whether the reduction of NF-L effected the caliber of 
axons in our patients we performed a morphometric analysis on the dermal 
nerves from our patients and controls. Our results demonstrated smaller axonal 
calibers in patients compared to controls (p< 0.01) (Figure 12B), providing 
further evidence of the NF role in the maintenance of the axonal diameter and 
supporting the feasibility of evaluating dermal nerves to address this question. 
 
Study of the nodal and paranodal regions 
A previous study of nodal architecture in NF deficient mouse showed 
normal placement, organization, and physical dimensions of nodes of Ranvier.48 
Our results demonstrated that sodium channels and Caspr are correctly 
localized in CMT2E patients (Figure 13), confirming that, despite the axonal NF 
deficiency, the molecular architecture of nodal and paranodal regions is not 
impaired in CMT2E. This observation supports the hypothesis that NF, as 
cytoskeletal components of the internodal domain of axons, are not required to 
position nodal and paranodal molecules. 
 
6. DISCUSSION 
 
6.1 Small fiber involvement in CMT1A 
Our results demonstrated length dependent small fiber abnormalities in 
all patients with CMT1A. Specifically, morphologic studies revealed a length-
dependent decrease in ENF density that correlated with functional measures of 
small fiber somatic and autonomic functions such as QST, reduced numbers of 
activated sweat glands, and decreased numbers of sudomotor nerve fibers. 
Thus, small nerve fiber abnormalities are clearly present in patients with 
CMT1A. 
 
Somatic nerves 
Sensory symptoms in CMT1A are generally attributed to length-
dependent large-fiber dysfunction (loss of touch, vibration, and position sense in 
the lower limbs). However, it has become increasingly evident that small-
diameter sensory nerves must also be affected, as was previously hypothesized 
and reported anecdotally.49,50 C unmyelinated and A- small myelinated nerve 
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fibers carry pain and temperature modalities that terminate in the skin as 
ENFs.51 The reduction in ENF density would therefore explain the length-
dependent reduction of pain and temperature sensation observed in most 
patients with CMT1A.52,53 Abnormalities in these nerves may also explain the 
pain that occurs in some patients with CMT1A. Pain is a common problem in 
CMT1A that may begin in childhood54 and impairs quality of life in both 
children55 and adults56,57. While much of the pain may be related to structural or 
joint abnormalities that are present from childhood,54 neuropathic pain has been 
estimated to occur in approximately 20% of patients with CMT1A.58 A study 
using LEPs to explore the nociceptive pathway in 16 patients with CMT1A 
reported a length-dependent impairment of A- fibers.59 Our study also supports 
the involvement of A- fibers in CMT1A since these are myelinated, and PMP22 
has a fundamental role in myelination.60 However, some of our findings (warm 
threshold abnormalities and ENF loss) also suggest an involvement of C fibers 
in CMT1A, although we cannot have morphologic evidence, since it is not 
possible to distinguish between C and A- fibers, whose cutaneous terminal 
branches are both unmyelinated.36,61 The involvement of small fibers in 
conditions affecting mainly large fibers has been previously reported,62-64 
implying that congenital or acquired mechanisms underlying the degeneration of 
large fibers may also affect small fibers. In CMT1A, abnormalities of the 
interaction between axon and Schwann cells may play a causative role in the 
distal degeneration of unmyelinated fibers, since PMP22 is also present in the 
plasma membrane of nonmyelinating Schwann cells.65 In addition, although the 
exact role of PMP22 is still under investigation, it has been observed that 
PMP22 overexpression may affect Schwann cell proliferation, differentiation, 
and death.66 The correlation of ENF loss with both MC density and tactile 
thresholds suggests that small fiber and large fiber degeneration in CMT1A 
follow a parallel course. ENF loss substantially increased with age, suggesting 
an additive effect on the modest decline in density observed in normal cohorts 
of controls.67 This decline could not be appreciated in our age- and sex-
matched control population representing a small cohort with a 
nonhomogeneous distribution of subjects among the different age decades. 
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Autonomic nerves 
The autonomic nervous system (ANS) is divided into sympathetic and 
parasympathetic components. Along the sympathetic pathway, only 
preganglionic sympathetic fibers are myelinated.68 Preganglionic sympathetic 
fibers originate from the spinal cord in the Clarke column and project to 
peripheral sympathetic ganglia. Preganglionic parasympathetic fibers originate 
from neurons located in the brainstem or sacral spinal cord and have a long 
course before the synapsis in the parasympathetic ganglia sited close to 
their target organs. In general, it is widely thought that signs and symptoms of 
ANS involvement such as urinary dysfunction, gastrointestinal disturbances, or 
orthostatic complaints are unusual in CMT1A patients.52 For example, prior 
reports have found that cardiac dysautonomia is relatively uncommon in 
CMT1A.69 Despite the low occurrence of CVR abnormalities, we observed a 
moderate loss of vasomotor nerves in all our patients. This discrepancy was in 
some way expected. In fact, we have learned from other longstanding 
autonomic conditions that cutaneous vasomotor denervation may not be 
associated with CVR abnormalities.70 Alternatively, we found abnormalities of 
sweating, sympathetically mediated, to be frequent. In our patient population, 
through the SFN-oriented questionnaire, hypohidrosis emerged as the most 
frequently reported autonomic symptom (60%). We evaluated the entire 
polysynaptic sudomotor pathway using SSR and also used DST to explore the 
function of postganglionic sudomotor nerves. SSR was present in all our 
patients but the amplitude of the potentials in the distal site was lower compared 
to healthy age and sex-matched controls. For diagnostic purposes only, the 
absence of the response is considered abnormal; however, SSR amplitude has 
been recently shown to correlate with sweat output.71 DST revealed 
hypohidrosis in 70% of our patients. DST is an objective and reliable test that is 
independent of patient cooperation.34 Both SSR and DST indicated a 
sudomotor functional impairment that goes parallel to the loss of sudomotor 
nerves. Taken together, our data demonstrate that some autonomic 
abnormalities are present in patients with CMT1A. Why some modalities are 
more affected than others and whether abnormalities result from dysfunction of 
presynaptic sympathetic fibers is beyond the scope of the present manuscript 
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but will be important in understanding the pathogenesis of clinical abnormalities 
in patients with CMT1A. 
We demonstrated through morphologic, physical, and psychophysical 
testing that small somatic nerve fibers and some sympathetic autonomic fibers 
are abnormal and cause symptoms in patients with CMT1A. Our findings build 
on a small but growing body of research that aims to demonstrate that CMT1A 
not only affects large myelinated fibers but also involves small fibers. Since 
SFN-related disturbances can negatively affect the clinical picture and the 
quality of life of patients with CMT1A, awareness of such symptoms by the 
clinician could lead to better treatment and an improvement of disease course. 
 
6.2 Large fiber involvement in different CMT subtypes 
Morphological data from patients with CMT is essential to understand the 
consequences of CMT causing mutations in patients and to compare 
abnormalities in humans with those in animal or cellular models of the same 
mutations. Sural nerve biopsies are no longer routinely performed in patients 
with CMT because they are invasive and not necessary for making a genetic 
diagnosis. We provided additional evidence that morphological data from 
minimally invasive skin biopsies offer similar information to that provided by 
sural nerve biopsies by identifying abnormalities in myelin or axons resulting 
from mutations in CMT causing genes. These morphological abnormalities 
provide interesting insights into potential pathomechanisms of axonal and 
demyelinating CMT as described below. 
 
Axonal loss 
Axonal degeneration is a major cause of long-term disability in both 
demyelinating and axonal CMT.72 Skin biopsy studies have previously 
demonstrated a loss of MC, a consequence of axonal loss, in patients with 
CMT173 and CMT1A23. In addition, recent observations using “in vivo confocal 
microscopy” demonstrated a significant correlation between MC loss and 
clinical disability as assessed by CMTNS.74 We have extended these 
observations in our studies by observing reductions in the density of both MC 
and IME in skin samples from multiple patients with axonal (TRPV4, RAB7, 
GDAP1) and “intermediate” (late onset MPZ and GJB1) forms of CMT in 
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addition to patients with CMT1A. We did not find a significant correlation 
between MC or IME loss and the CMTNS. However, our AR-CMT2K patient 
who presented with the most severe clinical impairment (CMTNS= 20) had a 
complete loss of MC and IME at skin biopsy. Taken together, our results 
demonstrate that axonal loss in CMT can be readily detected by skin biopsy. 
Since skin biopsies can be performed on multiple occasions these results also 
suggest their potential use as an outcome measure to detect axonal loss in 
longitudinal studies. 
 
Nodal gap length 
Nodes of Ranvier, paranodes and juxtaparanodes contain specialized 
regions of myelin and the axonal cyctoskeleton that play important roles in 
developing and maintaining the organization of myelin and the ensheathed 
axon.75 Altered axon-glial communication at this level has been hypothesized to 
contribute to axonal degeneration in patients with CMT1A and CMTX1.22,76 
Abnormalities and reorganization of paranodal regions have been clearly 
documented in sural and dermal nerve fibres from patients with CMT1A and 
CMTX1.22,77,78 Retraction of paranodal myelin appears as a widening of the 
nodal gap, which includes the true nodal space and part of flanking paranodal 
regions. Thus widening of nodal gaps can be used as a surrogate marker for 
changes occurring at nodes and/or paranodes. Evidence of widened gaps was 
observed in Trembler-J79 and Cx32-deficient mice80. We found that nodal gaps 
were significantly larger in patients with CMT1A than in other genotypes 
suggesting that widening of the nodal gap may be a feature of CMT subtypes 
that affect myelin. However, we also found that nodal gaps were wider in all 
other genotypes compared to controls suggesting that nodal gaps are abnormal 
even in patients with axonal forms of CMT. Abnormalities of nodal gaps have 
not been previously described in patients with CMT2 but experimental models 
of axonal degeneration have shown that early structural changes include 
paranodal myelin retraction.81,82 Moreover, retracted paranodal myelin sheaths 
are frequently associated with swollen axons83 which are thought to represent 
pre-degenerative phenomena84. These abnormalities were widely observed in 
dermal nerve fibres from our patients. Perhaps altered communications 
between axons and glia are common features for multiple forms of CMT 
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including those that primarily affect axons though widening may be greater in 
the de or dysmyelinating forms such as CMT1A. 
 
Internodal length 
Uniformly short internodes occur in dysmyelinating models such as 
periaxin null mice and have been hypothesized to cause slow nerve 
conductions such as are seen in these mice and in patients with periaxin 
mutations causing CMT4F.85 Uniformly shortened internodes in dermal nerve 
fibres were previously observed in skin biopsies from patients with CMT1A 
suggesting that developmental abnormalities in internode formation contributed 
to the slow nerve conductions in patients.23 However, shortened internodes 
have been reported in a sural nerve biopsy from a single late-onset axonal 
MPZ-mutated patient86 and in peripheral nerves of mutant mice deﬁcient for 
Cx3280. Patients with late onset CMT1B or with CMTX1 often have normal or 
only mildly slowed nerve conductions8 and minimal evidence of myelin 
abnormalities morphologically87,88. In the current paper we observed shortened 
internodes in all the CMT genotypes. Therefore, while uniformly shortened 
internodes may suggest a developmental abnormality in internode formation it is 
unclear whether they are always associated with abnormal myelin and whether 
they alone always cause slow conductions. We would not find it surprising that 
developmental abnormalities in axonal neuropathies could result in shortened 
internodes if we consider that reciprocal interactions between Schwann cells 
and axons are critical for the development of myelinated axons.89,90 Therefore 
mutations in both myelin and axon genes may developmentally impede 
internode formation. It will be interesting to investigate internodal length in skin 
biopsies with severe, early onset dysmyelinating CMT to determine whether it is 
the extent of the shortening of internodes rather than the presence or absence 
of shortening that best correlates with abnormalities of myelination. 
 
Effects of nodal and internodal length on nerve conduction velocity 
The question remains of why conduction velocities would be normal or 
near normal in axonal neuropathies if they, like demyelinating neuropathies also 
have shortened internodes. A potential answer to this question is provided in 
the recent study demonstrating that nerve conduction velocity in myelinated 
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nerves relies on internodal length until a threshold of internodal distance is 
reached, beyond which conduction speed does not increase further.91 We 
hypothesize that shortened internodes will therefore not cause slow conduction 
velocities until the shortening crosses this threshold. Consistent with this 
hypothesis, our patients with CMT1A had the shortest internodal length of all 
our patients. Moreover, CMT1A patients also had the widest nodal gap of our 
patients. The nodal/paranodal region represents an essential region for 
saltatory conduction in myelinated nerve fibres. Paranodal demyelination and 
abnormal exposure of voltage gated potassium channels at the paranodal 
regions can delay the rise time of action potentials, and may further contribute 
to NCV slowing. It may be that the extent of internodal shortening and nodal 
gap widening are both important in causing uniformly slow nerve conductions in 
CMT1A. 
 
6.3 Reduced neurofilament expression in cutaneous nerve fibers of 
patients with CMT2E 
Our results demonstrated a reduced expression of neurofilament and 
smaller axonal diameter in cutaneous nerve fibers of patients with CMT2E. In 
addition, our findings did not show NF aggregates in the axons, suggesting that 
their proximal localization in the cell body may lead to NF disruption distally. 
The cytoskeletal perturbation is specific for NF and does not affect other 
components involved in the axonal transport and scaffold, and in 
nodal/paranodal architecture. 
NF are the intermediate filaments of neurons and one of the major 
components of the neuronal cytoskeleton. They have a tripartite structure made 
up of a head domain which is involved in the assembly, a central rod domain 
that plays a role in the formation of filamentous structures, and a tail domain by 
which NF interacts with other components of the cytoskeleton.92 They are 
modified by post-translational changes and the most significant of these 
changes is phosphorylation. Their function appears to be intimately related to 
their phosphorylation state. NEFL-linked CMT2E mutations are distributed 
throughout the three functional domains and different mutations have been 
shown to cause distinct pathological effect.44,93 The mutation carried by our 
patients that leads to a substitution of glutamic acid to lysine at position 396 
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(Glu396Lys), occurs in a highly conserved motive at the end of the rod domain 
and several families with the same mutation as well as a transgenic mouse 
model have been reported in literature.42-44,93-95 The axons of the mutant mouse 
had fewer NF than those of the wild-type, and accordingly sural nerve biopsies 
from patients have shown the presence of axons either devoid or with a variable 
density of NF. Our results from both IHC and WB analysis are in keeping with 
these data, demonstrating reduced levels of NF in cutaneous nerve fibers. We 
think that a decrease in NF abundance in peripheral nerves might be a 
pathological marker of CMT2E and independent from the axonal loss. 
Specifically, the Glu396Lys mutation, as occurs in a protein domain involved in 
the dimerization process, may affect the ability of NF to assembly properly into 
filaments, disrupting the NF network and reducing the transport of NF into the 
axons. The loss of axonal NF distally may be a consequence of their 
accumulation proximally in both nerve fiber and cell body (as shown in 
transgenic models and iPSC-derived motor neurons from a CMT2E patient96), 
leading to the formation of aggregates and to subsequent alterations in the 
axonal cytoskeleton. The lack of NF aggregates distally supports this 
hypothesis. Notably, Fabrizi et al.43 reported the presence of giant axons with 
NF accumulation in sural nerve biopsies from four CMT2E patients carrying 
three different NEFL mutations, but not in their patient with the Glu396Lys 
mutation. This findings confirm that different mutations behave differently as far 
as disruption of NF organization is concerned, and that abnormalities of NF 
organization may be a marker of CMT2E. The possible alteration of axonal 
transport due to NF disruption does not involve other molecules that play a role 
in this process. Indeed, we did not find either an increase or a defect in the 
expression of acetylated -tubulin as respectively shown in NEFL knockout 
mice and in other models of axonal CMT.97,98 
A linear relationship between conduction velocity and fiber diameter is 
well known.99 Reduction in axon diameter decreases velocity, largely because 
the longitudinal resistance is higher. The most essential function of NF is 
regulating the axonal caliber and thereby the conduction velocity. NF are 
therefore particularly abundant in neurons with large diameter axons where fast 
impulse conduction velocities are crucial for proper functioning.100 Within the 
skin, NF is expressed by both A- and A-fibers, which are fast conducting 
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nerve fibres, but not by C-fibers that conduct more slowly.101 In transgenic mice 
the loss of NF-L resulted in axons with reduced diameters and slowed 
conduction velocities.97,102 Morphometric analysis of sural nerve biopsies from 
CMT2E patients disclosed decreased axonal diameters in myelinated fibers.42,43 
Our morphometric data demonstrated that reduced axonal diameters can also 
be detected in a less invasive way in cutaneous nerve fibers. These smaller 
axonal calibers can explain the slow conduction velocities observed in CMT2E, 
supporting the notion that conduction velocity can be slow even in the absence 
of demyelination or abnormalities of nodes and paranodes, since no significant 
myelin sheath, nodal or paranodal abnormalities were detected in our patients. 
Although the decreased axonal caliber observed in our patient might be the 
consequence of the loss of large diameter fibers. Indeed, mice in which NF-L 
has been deleted (NF-L -/-) showed a unimodal distribution of axon calibers with 
the large-sized myelinated axons being shifted to the small size axons, and a 
reduction in the large diameter fibres with loss of the bimodal spectrum have 
been reported in CMT2E patients as well.44,93,97 We believe that both 
phenomena occur in CMT2E and, along with the normal molecular architecture 
of nodes and paranodes, explain the reduced velocities detected in CMT2E 
patients.  
In conclusion, our study extends the pathology of CMT2E and provides 
clues to the pathogenesis, supporting the feasibility of skin biopsy to investigate 
its mechanisms. A better understanding of the pathomechanism underlying 
each single NEFL mutation can lead to identify a clear genotype-phenotype 
correlation. 
 
7. CONCLUSIONS 
Morphological data from patients with CMT is essential to understand the 
consequences of CMT causing mutations in patients and to compare 
abnormalities in humans with those in animal or cellular models of the same 
mutations. Sural nerve biopsies are no longer routinely performed in patients 
with CMT because they are invasive and not necessary for making a genetic 
diagnosis. We provided additional evidence that morphological data from 
minimally invasive skin biopsies offer similar information to that provided by 
sural nerve biopsies by identifying abnormalities in myelin or axons resulting 
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from mutations in CMT causing genes. The morphological abnormalities 
discussed above provide interesting insights into potential pathomechanisms of 
axonal and demyelinating CMT. 
In details, this study extends the information gained from skin biopsies on 
morphological abnormalities in various forms of CMT. We have shown the 
impairment of unmyelinated fibers in a demyelinated form of CMT. We have 
demonstrated that myelinated dermal nerves can be used to detect axonal 
degeneration and changes in nodal and paranodal regions as well as in 
internodal length in both axonal and demyelinating forms of CMT. It will be 
important to extend these investigations into patients with severe 
dysmyelinating forms of CMT such as early onset CMT1B or CMT4 to 
determine whether widening of nodal gaps or shortening of internodes is even 
more pronounced in these disorders. Moreover, our study extends the 
pathology of CMT2E and provides clues to the pathogenesis, supporting the 
feasibility of skin biopsy to investigate its mechanisms. A better understanding 
of the pathomechanism underlying each single NEFL mutation can lead to 
identify a clear genotype-phenotype correlation.  
Lastly, since this minimally invasive procedure can easily be repeated in 
the same subject, it could provide a morphological marker of disease 
progression in both natural history and clinical trials. 
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Table 1. Specific CMT types. 
 
Type Gene/locus Specific phenotype 
Autosomal dominant CMT1 (ADCMT1)   
CMT1A Dup 17p (PMP22) CMT1 
CMT1B MPZ CMT1/DSN/intermediate/CMT2 
CMT1C  SIMPLE CMT1 
CMT1D EGR2  CMT1/DSN 
CMT1E PMP22 point mutations CMT1/DSN 
CMT1F NEFL CMT2 but can have slow MNCVs with early onset and severe phenotype 
Hereditary neuropathy with liability to pressure palsies   
HNPP Del 17p/PMP22 point mutations Typical HNPP 
X-linked CMT1   
CMTX1 GJB1 Intermediate (male MNCVs < female MNCVs) 
Autosomal dominant CMT2 (ADCMT2)   
CMT2A MFN2 CMT2, usually severe, optic atrophy 
CMT2B RAB7 CMT2 with predominant sensory involvement  
CMT2C TRPV4 CMT2 with vocal cord and respiratory involvement 
CMT2D GARS CMT2 with predominant hand wasting/weakness or dHMN-V 
CMT2E NEFL CMT2 but can have slow MNCVs with early onset and severe phenotype 
CMT2F HSP27 (HSPB1) Classic CMT2 or dHMN-IIB 
CMT2L HSP22 (HSPB8) Classic CMT2 or dHMN-IIA 
CMT2K GDAP1 Classic CMT2 
Autosomal recessive demyelinating CMT (CMT4)   
CMT4A GDAP1 CMT1, early onset and severe phenotype/vocal cord and diaphragm paralysis 
CMT4B1 MTMR2 Severe CMT1/facial/bulbar/focally folded myelin 
CMT4C SH3TC2 CMT1, can be sever/scoliosis 
CMT4F PRX CMT1/more sensory/focally folded myelin 
CMT4J FIG4 CMT1 
Autosomal recessive axonal CMT (AR-CMT2)   
AR-CMT2A LMNA CMT2 proximal involvement and rapid progression/cardiomyopathy 
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AD, autosomal dominant; AR, autosomal recessive; CMT, Charcot–Marie–Tooth; Del, deletion; dHMN, distal hereditary motor 
neuropathy; DSN, Dejerine Sottas neuropathy; Dup, duplication; EGR2, early growth response 2; FIG4, FIG4 homologue; GARS, 
glycyl tRNA synthetase; GDAP1, ganglioside induced differentiation associated protein 1; GJB1, gap junction protein beta1; HNPP, 
hereditary neuropathy with liability to pressure palsies; HSP22, heat shock 22 kDa protein 8; HSP27, heat shock 27 kDa protein 1; 
LMNA, lamin A/C; MNCV, motor nerve conduction velocity; MFN2, mitofusin 2; MPZ, myelin protein zero; MTMR2, myotubularin 
related protein 2; NEFL, neurofilament light chain; PMP22, peripheral myelin protein 22; PRX, periaxin; RAB7, RAB7, member RAS 
oncogene family; SH3TC2, SH3 domain and tetratricopeptide repeats 2; SIMPLE, small integral membrane protein of the 
lysosome/late endosome. 
 
 
 
 
 
 
Table 2. Classic CMT phenotype.  
 
Onset II decade of life 
Onset symptom/sign Tripping and falling/balance problems 
Gait Steppage gait 
Cranial nerves  Usually normal 
Weakness  Symmetric, distal > proximal, LL > UL, anterior > posterior leg compartment  
Atrophy Hand and foot intrinsic muscles, leg muscles (inverted champagne bottle legs) 
Sensation Sensory loss in stocking/glove distribution 
Balance Impaired due to proprioception sense loss 
Deformities Claw hand, pes cavus/flat foot, hammer toes, scoliosis 
Deep tendon reflexes Diffusely absent but always involving the Achilles tendon 
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Table 3. Name, source and dilution of primary antibodies. 
 
Antigen (Abbreviation) Manufacturer  
 
Dilution 
Rabbit protein gene product 9.5 (rPGP) Biogenesis 1:400 
Mouse protein gene product 9.5 (mPGP) AbD Serotec  1:800 
Rabbit vasoactive intestinal peptide (rVIP) Immunostar 1:1000 
Mouse vasoactive intestinal peptide (mVIP) Santa Cruz Byotechnology 1:300 
Mouse collagen IV (mCOLIV) Chemicon  1:800 
Mouse myelin basic protein (mMBP) Santa Cruz Byotechnology  1:800 
Rabbit dopamine beta hydroxylase (rDβH) Chemicon  1:1000 
Rabbit substance P (rSubP) Immunostar  1:1000 
Rabbit calcitonon gene related peptide (rCGRP) Immunostar  1:1000 
Neurofilament-light chain (NF-L) Thermo Scientific  
1:200 (IHC) 
1:10000 (WB) 
Phosphorylated neurofilament (Phospho NF) Covance 1:200 
Alpha-tubulin (-tub) Cell Signaling  
1:800 (IHC) 
1:1000 (WB) 
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Table 4. Demographic data and CMTNS of 20 CMT1A patients. 
subject Sex age sensory 
symptoms  
motor 
symptoms 
legs 
motor 
symptoms 
arms 
pinprick vibration strength 
legs 
strength 
arms 
CMAP SNAP CMTES CMTNS 
P01 F 42 2 1 1 2 1 1 1 2 4 9 15 
P02 F 44 0 1 0 1 1 1 0 1 3 4 8 
P03 F 47 1 1 1 2 1 1 1 1 3 8 12 
P04 M 29 2 1 0 2 2 2 1 3 4 10 17 
P05 F 29 0 1 0 1 2 1 1 2 4 6 12 
P06 F 60 1 2 1 2 3 2 2 3 4 13 20 
P07 F 36 0 1 0 1 0 0 0 1 4 2 7 
P08 M 48 0 0 0 0 0 1 1 1 4 2 7 
P09 M 64 0 1 1 0 2 1 1 2 4 6 12 
P10 F 43 1 0 0 0 0 1 1 0 4 3 7 
P11 F 46 1 0 1 0 1 1 1 1 4 5 10 
P12 F 39 1 0 0 0 1 1 1 2 4 4 10 
P13 F 40 1 1 1 1 2 0 1 0 3 7 10 
P14 F 45 0 1 1 0 2 0 1 1 4 5 10 
P15 F 39 0 2 2 0 1 1 1 1 4 7 12 
P16 F 40 0 0 0 1 1 1 0 0 1 3 4 
P17 F 43 0 0 0 1 1 1 0 1 3 3 7 
P18 F 46 2 1 1 1 1 1 1 1 3 8 12 
P19 M 35 0 1 0 2 1 1 1 1 4 6 11 
P20 M 42 1 0 1 0 1 1 1 1 4 5 10 
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CMAP= compound motor action potential amplitude; SAP= sensory action potential amplitude; CMTES=Charcot–Marie–Tooth 
examination score; CMTNS=Charcot–Marie–Tooth neuropathy score. 
 
 
Table 5. Morphological data of CMT1A patients. 
 
Sex, M/F Age, y FT ENF/mm MC/mm2 IME/mm2 THIGH ENF/mm LEG ENF/mm 
Patients 5/15 42.9 (8.4) 3.3 (2.1) 9.4 (4.7) 28.0 (13.5) 22.4 (4.3) 8.5 (4.8) 
Controls 10/30 42.9 (8.4) 7.9 (2.4) 29.8 (9.3) 55.3 (20.3) 25.1 (5.4) 18.0 (5.2) 
p   <0.01 <0.01 <0.01 >0.05 <0.01 
 
FT ENF = Epidermal nerve fibers in fingertip; THIGH ENF= Epidermal nerve fibers in thigh; LEG ENF= Epidermal nerve fibers in leg; 
MC= Meissner corpuscle; IME= Intrapapillary myelinated fiber. Values are mean (SD). 
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Table 6. Demographic, SFN-SIQ, QST, and autonomic morphological and functional data of CMT1A patients. 
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P1 F 42 18 1,8 3,3 21,7 12,2 50 10,8 7 9,4 28,4 12,4 10 53,9 1,2 0,8 36 2,2 79,3 1,4 0 
P2 F 44 18 2,9 3,2 8,2 10,8 40 18,6 3,1 6,3 10,2 15 20 53,9 1,4 1 28 1,9 53,5 1,7 0 
P3 F 47 24 0,9 1,1 23,4 12,4 0 83,3 3,2 11,2 28,2 18 0 83,3 0,9 0,8 15 0,7 10,6 0,9 2 
P4 M 29 10 1,6 1,9 9,8 8,3 80 10,8 2,5 3,6 10,8 8,4 80 18,6 1,7 1,2 70 3,8 265,2 1,8 0 
P5 F 29 6 1,4 1,8 10,5 9,7 80 1,5 2,1 3,1 10,1 9,8 80 2,5 1,7 1,3 69 1,4 95,6 2,1 0 
P6 F 60 8 4,1 5,9 30,7 14,2 0 83,3 6 10 32 18 0 83,3 1,3 0,5 49 0,8 40,8 1,9 1 
P7 F 36 4 0,7 1,3 12,4 5 40 1,5 5,2 5,1 8,7 10,5 30 10,8 1,3 0,5 49 3,8 187,2 0,3 0 
P8 M 48 4 2,6 9,6 26 16,5 50 32,4 9,1 11,2 27,2 15,7 10 53,9 1,2 0,6 32 1,6 52,8 1,2 0 
P9 M 64 6 1,5 12,3 8,5 17,3 20 32,4 3,2 6,4 8,2 13,3 30 32,4 1 0,8 4 4,6 18,3 3 0 
P10 F 43 12 1,1 1,9 23,9 10,9 60 18,6 8,4 11,6 26,9 16,1 0 83,3 1,6 0,9 66 6,6 437,2 1,3 1 
Patients 3/7 
44.2 
(11.5) 
11.0 
(6.9) 
1.9 
(1.0) 
4.2 
(3.9) 
17.5 
(8.4) 
11.7 
(3.7) 
42.0 
(28.6) 
29.3 
(30.4) 
5.0 
(2.5) 
7.8 
(3.3) 
19.1 
(10.1) 
13.7 
(3.4) 
26.0 
(30.6) 
38.7 
(31.4) 
1.3 
(0.3) 
0.8 
(0.3) 
41.8 
(22.8) 
2.7 
(1.9) 
124.1 
(135.7) 
1.6 
(0.7) 
0.5 
(0.7) 
Controls 6/14 
44.2 
(11.5) 
n.a. 
1.4 
(0.6) 
1.7 
(0.5) 
9.9 
(4.3) 
7.5 
(2.2) 
85.2 
(15.6) 
2.2 
(1.1) 
3.1 
(1.3) 
7.6 
(2.8) 
8.9 
(3.0) 
8.9 
(3.0) 
78.4 
(17.5) 
3.4 
(3.5) 
2.1 
(0.4) 
1.7 
(0.4) 
75.4 
(17.5) 
9.0 
(3.2) 
681.2 
(332.9) 
5.4 
(4.8) 
n.a. 
p       >0.05 >0.05 <0.05 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 n.a. 
Abbreviations: CP= cold pain; CS= cold sensation; CVR= cardiovascular reflexes; HP= heat pain; ir= immunoreactive; NA= not 
applicable; PGP= protein gene product; QST= quantitative sensory testing; SFNSIQ= Small Fiber Neuropathy Symptoms Inventory 
Questionnaire; SNF= sudomotor nerve fiber; SSR= sympathetic skin response; TTH= tactile threshold; VIP= vasoactive intestinal 
peptide; WS= warm sensation. 
Thermal thresholds are expressed as °C ( from 32° baseline); pinprick is expressed as % of stimuli perceived as painful; TTH is 
expressed as mN; PGP-ir and VIP-ir SNF density are expressed as nm/m3; sweat gland density is expressed as number of 
glands/cm2; sweat output is expressed as nL/min; SSR amplitude is registered from feet after electrical stimulation of median nerve 
and is expressed as mV. The number of CVR tests that gave pathologic results is reported. SD are presented in parentheses. 
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Table 7. Clinical and skin biopsy features of the CMT group for the large fiber evaluation. 
 
 PMP22 MPZ GJB1 RAB7 TRPV4 GDAP1 Controls p value 
Individuals (n) 10 5 9 3 3 1 45  
Age (years)  40.4 + 5.4 52.8 + 12.3 48.4 + 13.6 45.6 + 2.5 42.0 + 16.0 31 46.5 + 10.6 NS 
b
 
Gender (M:F) 2:8 3:2 2:7 2:1 2:1 0:1 21:24  
MNCV (m/sec) 
a
  
21 + 6.1 
(6.2-27.6) 
38.9 + 4.0 
(33.1-42) 
42.2 + 7.3 
(29.7-48.4) 
48.5 + 6.1 
(41.5-52.4) 
47.6 + 4.1 
(43-51) 
39.3 
(31-43) 
NA  
CMTNS 
a
 
11.5 + 2.7 
(8-17) 
12 + 1.9 
(10-15) 
10.4 + 6.2 
(2-17)  
10 + 5.2 
(4-14) 
17.6 + 4.0 
(14-22) 
20 NA NS 
c
 
MC (per mm
2
) 
a
  
8.2 + 4.7 
(2.7-19.6) 
4.6 + 5.5 
(0-13.5) 
8.2 + 6.9 
(0-23.5) 
3.1 + 3.8
 
 
(0-7.6) 
0.2 + 0.4 
(0-0.8) 
0 
28.3 + 9.2 
(14.6-51.9) 
< 0.005 
c
 
IME (per mm
2
) 
a
 
28.2 + 18.7   
(1.5-59.8)
 
 
20.0 + 16.1  
(0-37.7) 
28.0 + 14.7 
(0-52.5) 
11.9 + 4.8 
(6.5-15.7) 
19.7 + 19
 
 
(3.4-41.9) 
0 
55.4 + 21.1 
(26.3-100) 
< 0.005 
c
 
Nodal gap length (m) a 
n= 263 
6.0 + 3.5 
(1.5-22.8) 
n= 92 
5.1 + 2.7
 
 
(1.7-18.4) 
n= 308 
4.9 + 2.0
 
 
(1.7-18.6) 
n= 62 
4.7 + 2.0
 
 
(2.1-13.6) 
n= 101 
4.4 + 1.5 
(2.1-9.1) 
n= 48 
4.3 + 1.4
 
 
(2.2-11.9) 
n= 234 
3.4 + 1.5
 
 
(1.5-11.6) 
< 0.0001 
c
 
Internodal length (m) a 
n= 90 
53.5 + 22.4  
(20.9-117.2)  
n= 23 
68.9 + 36.6  
(23.4-176.6) 
n= 79 
67.7 + 26.4  
(24.6-169.5) 
n= 27 
65.1 + 39.0 
(22.6-218.2) 
n= 49 
68.6 + 22.0
 
 
(36.3-145.3) 
n= 25 
60.9 + 24.1
 
 
(21.3-111.1) 
n= 107 
84.2 + 27.7
 
(36.5-188.3) 
< 0.009
 c
 
  
MNCV= motor nerve conduction velocity; CMTNS= Charcot-Marie-Tooth Neuropathy Score; MC= Meissner corpuscles; IME= 
intrapapillary myelinated endings; NS= not significant; a data are expressed as mean + standard deviation (range); b ANOVA analysis 
with the Bonferroni post hoc test; c two-group comparison by using Mann-Whitney U-test. 
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Table 8. Clinical features of CMT2E patients. 
Patients III.1 III.2 III.3 III.4 III.5 IV.1 IV.2 IV.3 IV.4 
Age at examination/sex  57/F 53/M 58/F 56/M 50/M 25/M 24/F 33/M 24/M 
Onset age/symptoms 
Adolescence/ 
Unsteady 
ankles 
Childhood/ 
Toe walker 
Adolescence/ 
Pes cavus 
Childhood/ 
Unsteady 
ankles 
Childhood/ 
Unsteady 
ankles 
Childhood/ 
Toe walker 
Childhood/ 
Balance 
Childhood/ 
Toe walker 
Childhood/ 
Unsteady 
ankles 
Distal/Proximal weakness 
UL 
(4-; 2; 4-)/ 
(1; 1; 1)/ 
(4+; 4+; 5) 
(4; 2; 4)/ (1; 2; 1)/ (1; 1; 1)/ (2; 3; 2)/ (5; 5; 4-)/ (4-; 3; 4-)/ (3; 4-; 3)/ 
Distal/Proximal weakness 
LL 
(4; 5)/ (0; 0)/ (4+; 5)/ 
(0; 1)/ 
(3; 5) 
(1; 1)/ (4; 5)/ / (4-; 4)/ (4-; 5)/ 
Ankle deep tendon reflexes Reduced Absent Absent Absent Absent Absent Normal Absent Absent 
Joint position sense UL/LL 
Normal/ 
Normal 
Normal/ 
Toe 
Normal/ 
Toe 
Normal/ 
Toe 
Normal/ 
Toe 
Normal/ 
Normal 
Normal/ 
Normal 
Normal/ 
Normal 
Normal/ 
Toe 
Vibration sense UL/LL 
Normal/ 
Knee 
Normal/ 
Knee 
Fingers/ 
Knee 
Elbow/ 
Knee 
Normal/ 
Knee 
Elbow/ 
Knee 
Normal/ 
Normal 
Normal/ 
Normal 
Normal/ 
Knee 
Pinprick UL/LL 
Normal/ 
Toe 
Normal/ 
Ankle 
Normal/ 
Toe 
Wrist/ 
Knee 
Normal/ 
Toe 
Normal/ 
Toe 
Normal/ 
Normal 
Wrist/ 
Ankle 
Normal/ 
Ankle 
Light touch UL/LL 
Normal/ 
Normal 
Normal/ 
Ankle 
Normal/ 
Ankle 
Normal/ 
Ankle 
Normal/ 
Normal 
Normal/ 
Toe 
Normal/ 
Normal 
Normal/ 
Normal 
Normal/ 
Ankle 
Ulnar MNCV (CMAP) 
40 m/s 
(3.1 mV) 
NR 
40 m/s 
(3.6 mV) 
NR 
37.3 m/s 
(1.5 mV) 
27 m/s 
(2.3 mV) 
41 m/s 
(9.5 mV) 
36.6 m/s 
(7.7 mV) 
39 m/s 
(3.2 mV) 
CMTNS (phenotype) 
16 
(moderate) 
30 
(severe) 
20 
(moderate) 
30 
(severe) 
23 
(severe) 
18 
(moderate) 
5 
(mild) 
15 
(moderate) 
17 
(moderate) 
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Abbreviations: UL= upper limbs; LL= lower limbs; MNCV= motor nerve conduction velocity; CMAP= compound muscular action potential; 
CMTNS= Charcot-Marie-Tooth neuropathy score; NR= no response; = weakness absent.  
Motor weakness based on Medical Research Council Scale: upper limb distal weakness assessed by first dorsal interosseous, abductor pollicis 
brevis and adductor digiti minimi; upper limb proximal weakness assessed by deltoids, biceps brachii and triceps. Lower limb distal weakness 
assessed by anterior tibialis and gastrocnemius; lower limb proximal weakness assessed by iliopsoas and quadriceps. Numbers are based on the 
side that gave the worst score. For sensory examination: normal is no decrease compared to the examiner; the level given is the highest level 
where a deficit was detected.  
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Figure 1. A. Wasting of distal muscles in lower limbs leading to inverted 
champagne bottle legs. B. Example of wasting of intrinsic muscles of the hands. 
C. Pes cavus with hammer toes. 
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Figure 2. Schematic drawing of a neuron, its axon and Schwann cells with the 
major genes associated with Charcot-Marie-Tooth disease represented with 
their respective function and cellular compartment. Adapted from Saporta MA, 
Shy ME. Inherited peripheral neuropathies. Neurol Clin 2013;31:597-619; with 
permission. 
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Figure 3. Pathologic findings in demyelinating Charcot-Marie-Tooth disease. A. 
Cross section of a sural nerve biopsy of a patient with demyelinating CMT 
showing numerous demyelinated axons (arrows) and occasional classical onion 
bulbs (asterisk). Thionine and acridine orange stain. Bar = 10 μm. B. Electron 
micrograph showing a demyelinated axon (asterisk) surrounded by some 
excess basal lamina. The Schwann cells associated  with small, unmyelinated 
axons are abnormally long and attenuated (arrows). Bar = 1 μm. Adapted from 
Saporta MA, Shy ME. Peripheral neuropathies; with permission.
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Figure 4. Pedigree of the CMT2E family.  
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Figure 5. Confocal images showing morphometric analysis methods. In A and 
B: PGP/MBP double-stained images exemplifying the procedures used to 
measure node (B2), internode (B3) and fiber diameter (B4) calculated as the 
mean value of four random measures along the internode. Measurements were 
performed on MBP channel as showed by arrowheads while PGP staining 
(arrow in B1) was necessary to check on axonal continuity. In C the nodal 
region on an image double stained with NF and MBP: branching originates 
always from nodes (arrowhead). In D1 and D2 the same image at higher 
magnification after splitting the two channels. Scale bar: 50 µm (A); 100 µm (C). 
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Figure 6. Somatic denervation in glabrous and hairy skin of CMT1A 
patient.  
Digital images from fingertip (A, B), thigh (C, D) and leg (E, F) show epidermal 
and dermal denervation in patients with CMT1A. A moderate length-dependent 
loss of epidermal nerve fibers is present in patients with CMT1A compared to 
controls (B, D, F compared to A, C, E). Morphological abnormalities 
(arrowhead) and loss of Meissner corpuscles and intrapapillary myelinated 
endings are also evident in B. In addition to degenerative signs, frequent 
aspects of nerve remodeling (clusters) are observed (arrowheads in D and F). 
Scale bar: 100 µm. COLIV= collagen IV; MBP= myelin basic protein; PGP= 
protein gene product.   
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Figure 7. Cutaneous autonomic denervation in CMT1A patient.  
Confocal images show, in patients compared to controls, loss of cholinergic 
sudomotor nerves (B compared to A), and loss of cholinergic and noradrenergic 
fibers in arteriovenous anastomoses (D compared to C) and arrector pili muscle 
(F compared to E). Scale bar: 100 µm. VIP= vasoactive intestinal peptide; DH= 
dopamine--hydroxylase. 
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Figure 8. (A) Correlation between density of sudomotor nerve fibers and 
activated glands in CMT1A patient. (B) Age effect on ENF density.  
 
 
 
  
55 
 
Figure 9. Confocal images of glabrous skin in CMT patients and controls. A 
moderate loss of Meissner corpuscles is observed in a patient with CMT1A (B) and 
a severe loss of Meissner corpuscles is present in a patient with RAB7 mutation (C), 
compared to a control (A). From D to F: abnormalities of myelinated fibers such as 
fragmentation (D) and swellings (arrowheads in E and F). G to I: disruption of 
nodal/paranodal architecture with elongation and asymmetry of the paranodes with 
expansion of neurofascin aggregation along the internode (arrows in H and I) 
compared to control (G). Scale bar:  200 µm (A, B, C);  30 µm (D, E, F); 50 µm (G, 
H, I). 
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Figure 10. Boxplots of internodal length in each CMT genotype and controls. Dark 
horizontal lines represent the median value, with the box representing the 25th and 
75th percentiles, the whiskers the lower and upper adjacent values, and outside 
values represented by dots. 
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Figure 11. Cutaneous nerve fibers from CMT2E patients show a lack of NF. 
(A) Confocal images of dermal axons stained with antibodies against PGP 9.5 (red), 
NF-L (green) and MBP (blue) in patient (IV, V) and control (I, II). A reduced or 
absent expression of NF is observed in patient compared to control. Confocal 
images of dermal nerve fibers stained with antibodies against -tubulin (red), NF-L 
(green) and PGP 9.5 (blue) in patient (VI) and control (III). No difference in the 
expression of -tubulin is found but a reduced NF labelling is still present in patient 
compared to control. Scale bar: 20µm. (B) Neurofilament (NF) fluorescence 
intensity (expressed as the percentage of the value of NF over the PGP intensity: 
NF/PGP ratio) between patients and controls. The ratio is significantly lower in each 
patient with respect to the controls (p < 0.01). (C) Western blot analysis of NF-L 
from skin of patients and control, normalized for -tubulin. NF-L expression is 
decreased in patients with a complete absence of NF-L band in two of them, while 
-tubulin expression is normal. (D) NF-L/-tubulin ratio is markedly reduced in 
patients compared to controls.  
 
58 
 
Figure 12. Electron microscopy images of dermal nerves in CMT2E (A). 
Morphometric analysis of axonal caliber (B). (A) Electron microscopy images of 
dermal axons in CMT2E patient. Arrowheads: myelinated axons; arrow: 
unmyelinated axons; asterisk: Schwann cells without axons (bands of Bungner). No 
NF aggregates were detected. Scale bar: 2 µm. (B) Morphometric analysis showed 
smaller axonal calibers in patients than in controls (p< 0.01). 
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Figure 13. Nodal/paranodal architecture of dermal nerves. Confocal images of 
dermal axons stained with antibodies against Caspr (red), sodium channels (green) 
and MBP (blue), show normal architecture of nodal and paranodal regions in both 
patient (III, IV) and control (I, II). Scale bar: 20µm. Panel IV and the two small left 
corner figures in the panels I and III are 3D images of single or few nodes of 
Ranvier at higher magnification.  
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